CO6382138A2 - N-cadherina: blanco para diagnosis y terapia de cáncer - Google Patents

N-cadherina: blanco para diagnosis y terapia de cáncer

Info

Publication number
CO6382138A2
CO6382138A2 CO11070978A CO11070978A CO6382138A2 CO 6382138 A2 CO6382138 A2 CO 6382138A2 CO 11070978 A CO11070978 A CO 11070978A CO 11070978 A CO11070978 A CO 11070978A CO 6382138 A2 CO6382138 A2 CO 6382138A2
Authority
CO
Colombia
Prior art keywords
cadherina
diagnosis
white
cancer therapy
cancers
Prior art date
Application number
CO11070978A
Other languages
English (en)
Inventor
Robert Reiter
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CO6382138A2 publication Critical patent/CO6382138A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

La presente invención proporciona métodos de diagnosis, proveyendo una prognosis y un blanco terapéutico para el tratamiento de cánceres que expresan n-cadherina, incluyendo cánceres de próstata y vejiga.
CO11070978A 2008-11-10 2011-06-08 N-cadherina: blanco para diagnosis y terapia de cáncer CO6382138A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/268,302 US8663635B2 (en) 2006-03-21 2008-11-10 N-cadherin: target for cancer diagnosis and therapy

Publications (1)

Publication Number Publication Date
CO6382138A2 true CO6382138A2 (es) 2012-02-15

Family

ID=42153657

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11070978A CO6382138A2 (es) 2008-11-10 2011-06-08 N-cadherina: blanco para diagnosis y terapia de cáncer

Country Status (13)

Country Link
US (2) US8663635B2 (es)
EP (1) EP2355850A4 (es)
JP (1) JP2012508259A (es)
KR (1) KR20110084528A (es)
CN (1) CN102271709A (es)
AU (1) AU2009313197A1 (es)
BR (1) BRPI0921454A2 (es)
CA (1) CA2743133A1 (es)
CO (1) CO6382138A2 (es)
IL (1) IL212800A0 (es)
MX (1) MX2011004979A (es)
RU (1) RU2011123654A (es)
WO (1) WO2010054397A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2009124281A2 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
JP2009530645A (ja) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
US20140274872A1 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
CN108540664B (zh) * 2018-03-30 2021-02-19 联想(北京)有限公司 一种开机方法及电子设备
EP3832309B1 (en) * 2018-08-03 2023-11-01 Cytogen, Inc. Composition for diagnosis of bone metastasis of cancer and kit comprising same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889157A (en) * 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6277824B1 (en) * 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
DE10008907A1 (de) 2000-02-25 2001-08-30 Haarmann & Reimer Gmbh Topische kosmetische Mittel enthaltend benzokondensierte oder heterocyclisch kondensierte 2-Hydrazino-1,3-heteroazole
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
EP2213684A3 (en) 2003-12-22 2011-05-18 Glaxo Group Limited Nogo-a antibodies for the treatment of Alzheimer disease
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20100278821A1 (en) * 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2009124281A2 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
JP2009530645A (ja) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US8559186B2 (en) 2008-04-03 2013-10-15 Qualcomm, Incorporated Inductor with patterned ground plane
US8703920B2 (en) * 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
EP2603521A4 (en) 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES

Also Published As

Publication number Publication date
KR20110084528A (ko) 2011-07-25
WO2010054397A3 (en) 2010-08-19
WO2010054397A2 (en) 2010-05-14
US20100119527A1 (en) 2010-05-13
US8663635B2 (en) 2014-03-04
BRPI0921454A2 (pt) 2016-01-05
EP2355850A4 (en) 2012-07-18
JP2012508259A (ja) 2012-04-05
IL212800A0 (en) 2011-07-31
EP2355850A2 (en) 2011-08-17
US20140220005A1 (en) 2014-08-07
RU2011123654A (ru) 2012-12-20
CN102271709A (zh) 2011-12-07
MX2011004979A (es) 2011-09-01
US9470689B2 (en) 2016-10-18
AU2009313197A1 (en) 2011-07-07
CA2743133A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
CO6382138A2 (es) N-cadherina: blanco para diagnosis y terapia de cáncer
ECSP12012024A (es) Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
NO20084546L (no) Diagnostikk og behandlinger for tumorer
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
ECSP11010971A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un fármaco oral o no oral antidiabético
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CR11485A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
ECSP15011764A (es) Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico
CR20120035A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
CO6612209A2 (es) Terapia antia-agiogénesis para el tratamiento de cáncer de mama previamente tratado
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
BR112013009143A2 (pt) método in vitro, uso e invenção
PL1954830T3 (pl) Sposoby i zestawy do prognozowania przebiegu raka sutka
BR112017028012A2 (pt) Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2
MX2012003287A (es) Uso de la identificacion microambiental de sparc en el tratamiento del cancer.

Legal Events

Date Code Title Description
FA Application withdrawn